Publications by authors named "Yujiro Ueda"

Claim this Profile
C
Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid.
Tomonori Araki, Tsuyoshi Shirakawa, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Yujiro Ueda

Int J Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy.
Hiro Tatetsu, Koji Kato, Atsushi Wada, Taichi Hirano, Shikiko Ueno, Yujiro Ueda

Int J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 Study.
Atsuko Kakihara, Shigeyuki Takeshita, Mototsugu Shimokawa, Taiga Otsuka, Shiho Arima, Yujiro Ueda

Asia Pac J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study.
Tomomi Koike, Yasunori Kawaguchi, Mototsugu Shimokawa, Taiga Otsuka, Kanami Furukawa, Yujiro Ueda

Ther Adv Med Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results from the NAPOLEON-2 study.
Kazuo Nishikawa, Taiga Otsuka, Mototsugu Shimokawa, Takashi Inagaki, Azusa Komori, Yujiro Ueda

BMC Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies.
Tomonori Araki, Machiko Kawahira, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Yujiro Ueda

Oncology· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
Keisuke Miwa, Reina Kawasaki, Mototsugu Shimokawa, Taiga Otsuka, Toshimitsu Tanaka, Yujiro Ueda

Front Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302).
Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, Taiga Otsuka, Yuki Sonoda, Yujiro Ueda

Ther Adv Med Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301).
Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Yujiro Ueda

Sci Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Yujiro Ueda

Sci Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Tomoko Kodama, Takashi Imajima, Mototsugu Shimokawa, Taiga Otsuka, Masahiro Kawahira, Yujiro Ueda

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Yujiro Ueda

Sci Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda

Sci Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Azusa Komori, Satoshi Otsu, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda

Int J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Yujiro Ueda

Sci Rep· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Yasushi Ide, Taiga Otsuka, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda

Anticancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.
Junichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, Machiko Kawahira, Shiho Arima, Yujiro Ueda

Oncology· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, Kenichiro Murayama, Shunya Nakashita, Yujiro Ueda

J Geriatr Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda

BMC Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, Akio Ido, Futa Koga, Yujiro Ueda

Pancreas· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel FOLFIRINOX for Recurrent Pancreatic Cancer After Resection.
Hiroki Taguchi, Taiga Otsuka, Mototsugu Shimokawa, Shiho Arima, Shinichi Hashimoto, Yujiro Ueda

Anticancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Taiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, Futa Koga, Yasunori Kawaguchi, Yujiro Ueda

Int J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Taiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, Futa Koga, Yasunori Kawaguchi, Yujiro Ueda

Int J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retroperitoneal Bulky Histiocytic Sarcoma Successfully Treated with Induction Chemotherapy Followed by Curative Surgery.
Masafumi Oto, Akiko Maeda, Taku Nose, Yujiro Ueda, Shima Uneda

Intern Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Yujiro Ueda, Nobuaki Matsubara, Ken-Ichi Tabata, Takefumi Satoh, Naoto Kamiya

Clin Genitourin Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis